Lanreotide Therapy in Carcinoid Syndrome: Prospective Analysis of Patient-Reported Symptoms in Patients Responsive To Prior Octreotide Therapy And Patients Naïve To Somatostatin Analogue Therapy in The Elect Phase 3 Study-Reference-Cited by-同舟云学术

Lanreotide Therapy in Carcinoid Syndrome: Prospective Analysis of Patient-Reported Symptoms in Patients Responsive To Prior Octreotide Therapy And Patients Naïve To Somatostatin Analogue Therapy in The Elect Phase 3 Study

Published:2018-03 Issue:3 Volume:24 Page:243-255
ISSN:1530-891X
Container-title:Endocrine Practice
language:en
Short-container-title:Endocrine Practice

Author:

Fisher George A.,Wolin Edward M.,Liyanage Nilani,Lowenthal Susan Pitman,Mirakhur Beloo,Pommier Rodney F.,Shaheen Montaser,Vinik Aaron I.

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism

Reference40 articles.

1. Effects of TZD use and discontinuation on fracture rates in ACCORD bone study;Schwartz;J Clin Endocrinol Metab,2015

2. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells;Kanazawa;BMC Cell Biol,2007

3. Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients;Jehle;Eur J Intern Med,2003

4. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications;Yamamoto;J Bone Miner Res,2009

5. Bariatric surgery versus intensive medical therapy for diabetes-5-year outcomes;Schauer;N Engl J Med,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan;Oncology and Therapy;2024-08-31

2. Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors;Reviews in Endocrine and Metabolic Disorders;2023-12-05

3. Sex differences in carcinoid syndrome: A gap to be closed;Reviews in Endocrine and Metabolic Disorders;2022-03-16

4. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials;Journal of Neuroendocrinology;2021-08-16

5. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria;Experimental and Clinical Endocrinology & Diabetes;2021-07